Literature DB >> 8096266

Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus.

O Vaarala1, G Alfthan, M Jauhiainen, M Leirisalo-Repo, K Aho, T Palosuo.   

Abstract

Serum lipoproteins contain phospholipids and modified low-density lipoprotein (LDL) may thus act as a target for antiphospholipid antibodies. Raised concentrations of IgG antibodies against oxidised LDL were found in 47 of 61 (80%) patients with systemic lupus erythematosus (SLE). 46% of patients also had raised concentrations of IgG anticardiolipin antibodies. Binding of anticardiolipin antibodies to solid-phase cardiolipin was inhibited by oxidised LDL but not by native LDL in 16 of 21 sera from SLE patients. These observations suggest crossreactivity between antiphospholipid antibodies, which are closely associated with thrombosis in SLE, and antibodies to oxidised LDL, thus providing a possible link between thrombotic and atherosclerotic complications in SLE.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096266     DOI: 10.1016/0140-6736(93)91213-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  54 in total

1.  Inflammation-mediated rheumatic diseases and atherosclerosis.

Authors:  S Manzi; M C Wasko
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

Review 2.  Association of anticardiolipin antibodies with vascular injury: possible mechanisms.

Authors:  Y S Haviv
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

3.  Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL.

Authors:  B P Swets; D A Brouwer; J W Tervaert
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 4.  Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis.

Authors:  José Delgado Alves; Bruno Grima
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 5.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 6.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 7.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

8.  Food restriction and fish oil suppress atherogenic risk factors in lupus-prone (NZB x NZW) F1 mice.

Authors:  Alagarraju Muthukumar; Khaliquz Zaman; Richard Lawrence; Jeffery L Barnes; Gabriel Fernandes
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

9.  Autoantibodies to malondialdehyde-modified epitope in connective tissue diseases and vasculitides.

Authors:  A Amara; J Constans; C Chaugier; A Sebban; L Dubourg; E Peuchant; J L Pellegrin; B Leng; C Conri; M Geffard
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

10.  [Oxidatively modified lipoproteins and their antibodies in patients with antiphospholipid syndromeand systemic lupus erythematosus].

Authors:  B Roch; S Kopprasch; J Pietzsch; H-E Schröder
Journal:  Z Rheumatol       Date:  2004-08       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.